| Literature DB >> 32348485 |
Qing-Lei Zeng1, Zu-Jiang Yu1, Jian-Jun Gou1, Guang-Ming Li2, Shu-Huan Ma2, Guo-Fan Zhang3, Jiang-Hai Xu4, Wan-Bao Lin5, Guang-Lin Cui6, Min-Min Zhang2, Cheng Li2, Ze-Shuai Wang7, Zhi-Hao Zhang1, Zhang-Suo Liu1.
Abstract
Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier.Entities:
Keywords: Convalescent plasma therapy; Coronavirus disease 2019 (COVID-19); Fatality; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Survival rate; Viral shedding
Mesh：
Substances：
Year: 2020 PMID： 32348485 PMCID： PMC7197534 DOI： 10.1093/infdis/jiaa228
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226